Cite
HARVARD Citation
Schaer, D. et al. (n.d.). Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Journal for immunotherapy of cancer. p. . [Online].